Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510887 · ClinicalTrials.gov registry record · Phase 2
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00510887 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 14 participants.
The verdict
NCT00510887, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of combining bortezomib (Velcade) with rituximab, fludarabine, mitoxantrone, and dexamethasone in treating patients with follicular cell lymphoma.
Interventions
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Dexamethasone
- DRUG Mitoxantrone
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510887
The ClinicalTrials.gov registry entry for NCT00510887 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00510887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510887 about?
NCT00510887 is a clinical study titled "Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma". The purpose of this study is to evaluate the effectiveness and safety of combining bortezomib (Velcade) with rituximab, fludarabine, mitoxantrone, and dexamethasone in treating patients with follicular cell lymphoma.
What is the current status of trial NCT00510887?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-01. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00510887?
The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG), Dexamethasone (DRUG), Mitoxantrone (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00510887?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.